Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13716184 | 0.82 | KMT2A (0.33) | KMT2AALDH1A1HSD17B10MAPK1L3MBTL1 | |
| SCHEMBL6363249 | 0.78 | PTPN1 (0.39) | KMT2AALDH1A1PTPN1 | |
| SCHEMBL23617097 | 0.76 | L3MBTL1 (0.35) | KMT2AALDH1A1L3MBTL1PTPN1 | |
| SCHEMBL2062684 | 0.75 | ALDH1A1 (0.44) | KMT2AALDH1A1HSD17B10L3MBTL1CRHBP | |
| SCHEMBL24271114 | 0.74 | LMNA (0.33) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL9730908 | 0.74 | — | — | |
| SCHEMBL12041925 | 0.74 | ALDH1A1 (0.45) | KMT2AALDH1A1HSD17B10L3MBTL1CRHBP | |
| SCHEMBL15564118 | 0.73 | KMT2A (0.40) | KMT2AALDH1A1HSD17B10MAPK1L3MBTL1 | |
| SCHEMBL5171537 | 0.72 | PTPN1 (0.45) | KMT2AALDH1A1L3MBTL1CRHBPCRHR2 | |
| SCHEMBL18098832 | 0.72 | ALDH1A1 (0.44) | KMT2AALDH1A1L3MBTL1CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038357-A1 | SYNTHESIS OF SUBSTITUTED TETRACYCLIC CARBOXYLIC ACIDS AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-22 | — | — | WO | claimed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4727943-A1 | INHIBITORS OF MET KINASE | Celyn Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12595245-B2 | Inhibitors of MET kinase | CELYN THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260048138-A1 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| EP-4612149-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-4608826-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-09-03 | — | — | EP | disclosed |
| EP-0265230-A1 | Substituted-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids, derivatives thereof, pharmaceutical compositions comprising the compounds, and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4665079-A | QUINOLINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4663457-A | BACTERICIDES | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | disclosed |
| US-4638067-A | NAPHTHYRIDINE AND QUINOLINE CARBOXYLIC ACIDS | WARNER-LAMBERT CO. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0172651-A1 | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-02-26 | — | — | EP | disclosed |
| US-4571396-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1986-02-18 | — | — | US | disclosed |
| EP-0159174-A2 | Substituted naphthyridine-, quinoline- and benzoxazine- carboxylic acids as antibacterial agents and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-10-23 | — | — | EP | disclosed |
| US-4547516-A | Antisecretory agents derived from meldrum's acid | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0153828-A2 | 1-cyclopropyl-1, 4-dihydro-6-fluoro-4-oxo-1, 8-naphthyridine-3-carboxylic acids; their derivatives and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-09-04 | — | — | EP | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | KMT2A 4535/4885ALDH1A1 4013/4885HSD17B10 930/4885 |
| US-12595245-B2 | Inhibitors of MET kinase | MET, ABL1, ERBB2 | KMT2A 422/4885ALDH1A1 2585/4885HSD17B10 4291/4885 |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | KMT2A 715/4885ALDH1A1 3820/4885HSD17B10 3742/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | KMT2A 4742/4885ALDH1A1 1848/4885HSD17B10 571/4885 |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | KMT2A 3675/4885ALDH1A1 397/4885HSD17B10 965/4885 |
| US-20260048138-A1 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | PIK3R5, PIK3R4, PIK3CD | KMT2A 3948/4885ALDH1A1 4253/4885HSD17B10 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.